Drugs / Autologous DC vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04166006 | Dec 2019 → Apr 2027 expected | head and neck neoplasm, neuroendocrine neoplasm, soft tissue sarcoma | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Recruiting | No outcome recorded |
| Phase 2 | NCT03226236 | Mar 2016 → Mar 2019 | renal cell carcinoma | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous DC vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03226236 ↗ |
| Modality | Cell therapy | “The intradermal autologous dendritic cell vaccine loaded with autologous tumor homogenate” NCT03226236 ↗ |